

# United States Plasma Fractionation Market Set to Surge: Innovations and Growth Opportunities Unveiled 2025-2032

The Plasma Fractionation Market is estimated to reach at a CAGR of 7% during the forecast period 2024-2031.

AUSTIN, TX, UNITED STATES, October 10, 2025 /EINPresswire.com/ -- Overview of the Market:



The Plasma Fractionation Market is rapidly expanding, driven by rising demand for plasma-derived therapies, technological advancements, and increasing prevalence of chronic diseases."

DataM Intelligence

The Global <u>Plasma Fractionation Market</u> has witnessed significant growth over the past decade, driven by rising demand for plasma-derived therapies, advancements in biopharmaceutical technologies, and increasing prevalence of chronic diseases such as hemophilia, immunodeficiency disorders, and other blood-related conditions. Plasma fractionation, a process of separating plasma into its individual components such as albumin, immunoglobulins, and clotting factors plays a critical role in producing lifesaving therapies that address these medical conditions. The market's growth is further fueled by innovations in

fractionation technologies and increased awareness among healthcare professionals and patients about the benefits of plasma-derived products.

To Download Sample Report Here: <a href="https://www.datamintelligence.com/download-sample/plasma-fractionation-market">https://www.datamintelligence.com/download-sample/plasma-fractionation-market</a>

The Immunoglobulin segment dominates the market due to its extensive use in treating immune disorders, while North America leads geographically, driven by a strong healthcare infrastructure, robust plasma donation programs, and significant investments in plasma fractionation facilities. Europe follows closely, with increasing adoption of advanced therapies and government initiatives supporting plasma collection and processing.

Key Highlights from the Report:

The Immunoglobulin segment is projected to register the highest growth due to increasing

demand for immune therapies.

North America is the largest regional market, supported by advanced healthcare infrastructure and high plasma donation rates.

Technological advancements in plasma fractionation methods, such as solvent/detergent treatment and chromatography, enhance product quality and yield.

Rising prevalence of chronic blood disorders fuels demand for plasmaderived products.

Biopharmaceutical companies are expanding production capacities to meet growing global demand.
Strategic partnerships and mergers are shaping the competitive landscape of the market.



## Market Segmentation:

The Plasma Fractionation Market is broadly segmented based on product type, application, and end-user.

By Product Type: The market includes albumin, immunoglobulins, coagulation factors, and others. Immunoglobulins hold the largest market share due to their wide therapeutic application in treating autoimmune diseases and primary immunodeficiency disorders. Albumin products are extensively used for blood volume expansion and liver disease management, while coagulation factors are vital in hemophilia treatment.

By Application: Plasma-derived products are widely used in hematology, immunology, neurology, and critical care settings. Hematology leads due to high prevalence of bleeding disorders and the growing adoption of clotting factor therapies. Immunology applications are expanding as immunoglobulin therapies gain prominence in autoimmune and inflammatory disorders.

By End-User: Hospitals, clinics, and research institutes are the primary end-users. Hospitals dominate the market, accounting for the majority of consumption due to the increasing number of patients requiring plasma-derived therapies and emergency care services.

Speak to Our Analyst and Get Customization in the report as per your requirements: <a href="https://www.datamintelligence.com/customize/plasma-fractionation-market">https://www.datamintelligence.com/customize/plasma-fractionation-market</a>

# Regional Insights:

North America remains the leading regional market due to strong plasma donation systems in the U.S. and Canada, coupled with advanced biopharmaceutical manufacturing capabilities. The presence of major market players and supportive regulatory frameworks further strengthens market dominance.

Europe is experiencing steady growth, particularly in Germany, France, and the U.K., driven by government-supported plasma collection initiatives and increasing awareness about plasma therapies.

Asia-Pacific represents a high-growth region, led by countries like China, Japan, and India, where rising healthcare expenditure, growing awareness, and improving plasma collection infrastructure are boosting market expansion.

Latin America and the Middle East & Africa are emerging markets, benefiting from increasing access to healthcare facilities, rising incidence of blood disorders, and growing adoption of plasma-derived therapies.

# Market Dynamics:

#### Market Drivers:

The Plasma Fractionation Market is propelled by increasing prevalence of chronic blood and immune-related disorders, rising global demand for immunoglobulin therapies, and technological innovations in fractionation processes. The expansion of plasma donation centers and supportive healthcare regulations in developed regions further enhance market growth.

### Market Restraints:

High costs associated with plasma-derived therapies, stringent regulatory approvals, and challenges in plasma collection and storage can limit market expansion. Additionally, risks of contamination and supply chain constraints pose operational challenges for manufacturers.

# Market Opportunities:

Emerging markets present lucrative opportunities due to growing healthcare infrastructure, increasing patient awareness, and rising disposable incomes. Strategic collaborations, technological advancements, and expansion of plasma fractionation capacities are expected to unlock new revenue streams for market players.

# Frequently Asked Questions (FAQs)

How big is the Plasma Fractionation Market globally? Who are the key players in the plasma fractionation industry? What is the projected growth rate of the plasma fractionation market? What is the market forecast for 2032?

Which region is estimated to dominate the industry through the forecast period?

Company Insights:

Key players operating in the Plasma Fractionation Market include:

**CSL** 

Grifols

China Biologic Products Shire (Takeda Pharmaceutical Company) Octapharma Plasma, Inc. Kedrion S.p.A

Sanguin

LFB SA

**Recent Developments:** 

**United States:** 

Grifols Acquires Plasma Centers

In March 2025, Grifols acquired 14 plasma collection centers from Immunotek for approximately \$135 million, expanding its U.S. operations.

Plasma Market Growth Projections

The U.S. plasma fractionation market is projected to grow from \$5.1 billion in 2025 to \$8.2 billion by 2035, driven by increasing demand for plasma-derived therapies.

Japan:

Market Expansion Forecast

Japan's plasma fractionation market is expected to grow from \$1.5 billion in 2025 to \$2.7 billion by 2035, with a CAGR of 6.02%, fueled by rising chronic disease prevalence.

Immunoglobulin Demand Surge

Immunoglobulins remain the largest revenue-generating product in Japan's plasma fractionation market, with expectations of continued growth through 2030.

Unlock 360° Market Intelligence with DataM Subscription Services: <a href="https://www.datamintelligence.com/reports-subscription">https://www.datamintelligence.com/reports-subscription</a>

Conclusion:

The Plasma Fractionation Market is poised for robust growth, driven by rising demand for

plasma-derived therapies, advancements in fractionation technologies, and expanding healthcare infrastructure worldwide. While challenges such as high treatment costs and regulatory complexities exist, opportunities in emerging regions and technological innovations provide strong growth potential. Leading players continue to invest in production capacity, research, and strategic partnerships, ensuring that plasma fractionation remains a critical component of modern healthcare solutions.

Related Reports:

Plasma Protein Therapeutics Market

## Plasma Protease C1-Inhibitor Treatment Market

Sai Kiran
DataM Intelligence 4Market Research
+1 877-441-4866
Sai.k@datamintelligence.com
Visit us on social media:
LinkedIn
X

This press release can be viewed online at: https://www.einpresswire.com/article/857100938

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.